Rheutrop retard

Quick links

Choose a section

Quick links to important sections

Advertisements

Rheutrop retard

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Rheutrop retard

Property Description
Active ingredient Acemetacin (Prodrug)
Form Modified-Release Hard Capsules (Retard Kapseln)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Management of pain and inflammation
Origin Synthetic derivative (Indoleacetic acid ester)

What Type of Medicine is Rheutrop retard?

Rheutrop retard is an oral medicinal product containing the single active substance Acemetacin, and it is formally classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This synthetic compound is recognized as an indoleacetic acid derivative, positioning it among the subset of NSAIDs clinically used for significant anti-inflammatory and analgesic effects.

The medicine's general purpose is to provide relief from persistent pain and inflammation. Pharmacological studies confirm Acemetacin's efficacy in addressing symptoms common in musculoskeletal and joint conditions, supporting the drug's role in easing the discomfort and swelling caused by inflammation.

Acemetacin: The Prodrug and Its Composition

The core component, Acemetacin, is defined by its structure as a prodrug, which means it is pharmacologically inactive when taken and must be converted by the body to yield the potent active substance, Indomethacin. This chemical relationship is a key differentiating feature, as Acemetacin is the carboxymethyl ester of Indomethacin, a structural modification designed to optimize delivery.

This prodrug strategy is utilized to enhance the drug's tolerability profile. Clinical experience has indicated that this indirect delivery mechanism contributes to reduced irritative effects on the stomach lining compared to the direct administration of its metabolite, Indomethacin. This design aims at improving patient comfort and safety.

The Meaning of 'Retard': Modified-Release Capsules

The name Rheutrop retard refers to its specialized pharmaceutical form: a modified-release hard capsule. This oral delivery system is a distinctive feature of this product, ensuring that Acemetacin is released and absorbed slowly and consistently over an extended duration, unlike immediate-release formulations. This sustained-release mechanism is vital for maintaining steady therapeutic levels, which is often clinically beneficial for managing long-term or chronic inflammatory symptoms.

Advertisements

What side effects are possible with Rheutrop retard?

Possible Side Effects and Safety Information

The safety profile for Acemetacin (Rheutrop retard), like all Non-steroidal Anti-inflammatory Drugs (NSAIDs), is officially categorized by frequency and the body system affected, according to regulatory standards.

Adverse Reaction Scope

The most common adverse reactions documented in official labeling typically involve Gastrointestinal Disorders (e.g., dyspepsia, nausea, abdominal pain) and Nervous System Disorders (e.g., headache, dizziness). These are generally classified as Common, affecting up to 1 in 10 patients.

Less frequent, but documented, effects include Uncommon reactions such as hypersensitivity reactions (rash) and elevated liver enzyme values. Rare reactions, affecting up to 1 in 1,000 patients, include serious gastrointestinal events like bleeding and ulceration, and changes to blood cell counts.

Serious Safety Concerns

Official regulatory documents emphasize the risk of serious adverse reactions, which include:

  • Gastrointestinal Perforation and Severe Bleeding: These events may occur at any time and without warning. The risk is documented as being higher at the beginning of treatment and associated with long-term use.
  • Serious Arterial Thrombotic Events: As a class effect, an increased risk of events like Myocardial Infarction and Stroke is documented, which increases with the duration of use.
  • Severe Organ Impairment: Acute renal failure and severe hepatic injury are documented concerns.

Population and Timing Constraints

Safety notes explicitly state that Older Adults have an increased risk for serious adverse reactions, particularly GI bleeding and perforation. The medication is officially contraindicated in patients with active gastrointestinal ulceration, severe heart failure, severe renal or hepatic impairment, and during the third trimester of pregnancy. These constraints are defined in the official regulatory product information to limit use where risks are highest.

Advertisements

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations: Initial presentations may include nausea, vomiting, abdominal pain, headache, dizziness, and confusion. Severe poisoning is documented by the onset of seizures, marked drowsiness, tinnitus, or other neurological and sensory disturbances.
Physiological systems affected (as stated in label): Severe intoxication carries the risk of damage to the Gastrointestinal system (including bleeding and perforation), Renal function (acute failure), the Hepatic system (hepatotoxicity), and the Central Nervous System.
Dose-related or exposure-related factors (if applicable): Symptoms and severity are generally associated with the ingestion of high doses; the modified-release formulation may necessitate extended observation due to slow absorption.
Population-specific overdose notes (if applicable): No unique population-specific management protocols are explicitly detailed in the official overdose section.
Emergency-response statements (as written in official documents): Management relies on symptomatic and supportive treatment. No specific antidote is known. Procedures such as gastric lavage or administration of activated charcoal may be considered.
When immediate medical help is required (label-derived phrasing only): Immediate medical attention must be sought. It is required to contact emergency services or a Poison Control Center.

Overdose Classifications (High-Level)

Category Official Regulatory Statements
Severity classification (as defined in official documents): The profile notes the potential for severe or fatal outcomes associated with major organ damage.
Overdose-context constraints (as defined in official documents): Close hospital monitoring of vital signs, fluid balance, and renal and hepatic function is required following intoxication.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with gastrointestinal and neurological manifestations, including headache, confusion, nausea, and vomiting.
  • Severe intoxication carries the risk of life-threatening organ damage, specifically gastrointestinal perforation and acute renal failure.
  • Immediate medical attention must be sought and a Poison Control Center contacted when an overdose is suspected.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the official overdose profile by detailing the expected range of clinical manifestations and explicitly listing the most serious, potentially fatal outcomes. This profile dictates the emergency actions, which uniformly mandate that patients seek immediate medical help because management is confined to supportive care and there is no specific antidote available.

Advertisements

Therapeutic Uses of Rheutrop retard

What Rheutrop Retard Treats: Main Uses and Benefits

This medication is used for managing the persistent pain and underlying inflammation associated with chronic joint disorders. Its use is relevant for therapeutic support in conditions characterized by periods of heightened symptoms, including Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It generally provides symptomatic relief that helps patients cope more steadily with the daily burden of these long-term conditions.

The drug is also applied during phases of heightened symptomatic discomfort, such as an acute attack of gouty arthritis, episodes of inflammatory Soft-Tissue Rheumatism, or pain following post-traumatic injuries and postoperative procedures. The therapy is commonly used to help address painful swelling and acute symptoms, which supports general well-being and assists with maintaining functional stability.

“This medication is commonly used to help manage symptoms related to inflammatory or irritative states across various musculoskeletal domains.”

Quick Fact: Relief for Persistent Pain and Swelling

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Rheutrop retard?

Eligibility to use Rheutrop retard (Acemetacin) is strictly defined by regulatory guidelines, primarily covering adults but imposing several important restrictions and absolute contraindications.

Absolute Contraindications

This medicine is formally contraindicated and must not be used by individuals with:

  • Known hypersensitivity to Acemetacin, its active metabolite Indomethacin, or other NSAIDs.
  • Active or history of recurrent peptic ulceration or gastrointestinal bleeding.
  • Active bleeding or severe heart failure.
  • Pregnancy during the third trimester.

Age and Physiological Restrictions

Population Official Regulatory Status
Children and Adolescents Not recommended (Use not established)
The Elderly Use with caution (Lowest dose, shortest duration)
Pregnancy (1st/2nd Trimester) Not recommended unless clearly necessary
Breastfeeding Should be avoided

Eligibility is also restricted for patients with severe renal impairment (must be avoided) and requires caution for those with moderate hepatic impairment or pre-existing cardiovascular conditions, as stated in the product labeling.

Advertisements

What should I know about interactions with other medicines?

Rheutrop retard contains acemetacin, a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its interaction profile is defined by its inhibitory effect on prostaglandin synthesis, which can lead to both pharmacokinetic and pharmacodynamic interactions with several classes of medications.

Documented Interactions

Interacting Product Category Potential Effect & Condition
Other NSAIDs (including high-dose salicylates) Increased risk of gastrointestinal bleeding and ulceration; concurrent use is generally not recommended.
Anticoagulants (e.g., Warfarin) and Antiplatelets Enhanced risk of bleeding or hemorrhage; requires close monitoring of coagulation status.
Diuretics & Antihypertensives (ACE inhibitors, ARBs) Reduced blood pressure control and increased risk of acute renal failure, especially in volume-depleted or elderly patients.
Lithium and Methotrexate Increased plasma concentrations of these drugs due to reduced renal excretion by acemetacin, requiring plasma level monitoring.
Corticosteroids and SSRIs Increased risk of gastrointestinal ulceration or bleeding.

Timing-Based Restriction

Acemetacin should not be used for 8 to 12 days following the administration of Mifepristone, as it may interfere with the intended effect of Mifepristone.

Summary

The regulatory documents emphasize that combinations involving other NSAIDs or agents that increase bleeding risk are typically contraindicated or require extreme caution and professional oversight. Interactions with antihypertensives and certain cytotoxic agents are primarily driven by the drug's impact on renal function and excretion pathways.

Advertisements

Mechanism of Action

Rheutrop retard acts primarily through its active metabolite, indometacin, to modulate key biochemical pathways. The core mechanism involves the reversible inhibition of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By targeting these enzymes, the metabolite prevents the conversion of arachidonic acid into various pro-inflammatory lipid mediators.

This enzymatic block leads to the suppression of prostaglandin and thromboxane synthesis. The resulting reduction in these crucial mediators decreases the formation rate of specific signaling molecules, thereby modulating pathway activity within targeted systems. The drug also engages mechanisms that influence the activation and migration of various leukocytes, such as neutrophils, which contributes to attenuating the cascade of physiological responses in areas characterized by heightened inflammatory signaling. This overall action influences the magnitude and equilibrium of downstream molecular signaling.

Advertisements

Dosage and Administration Information

The administration of Rheutrop retard is strictly defined by its official dosage form as a modified-release hard capsule containing 90 mg of Acemetacin, designated for oral administration only.

Administration Scope

The integrity of the capsule is essential for its intended function; consequently, it must be swallowed whole with a glass of water and must not be crushed or chewed to prevent the rapid release of the active substance. The typical daily dosing regimen ranges from 120 mg to 180 mg, achieved by taking the 90 mg capsule in divided doses. A higher maximum daily dose of 300 mg is authorized for initial, short-term management of acute inflammatory conditions.

Contextual and Population Rules

The frequency of use is generally once or twice daily, which is enabled by the modified-release formulation. Administration should occur with food, milk, or an antacid to help minimize potential gastrointestinal irritation. Official labeling advises that the medicine be used with particular care in older adults, often necessitating that treatment is initiated at the lower end of the established dosing range.

Procedural Structure and Protocol

The governing principle for the use of this medicine is to employ the lowest effective dosage for the shortest possible duration necessary to address the condition. The overall course of use is variable, spanning from defined short-term periods for acute episodes to an extended, long-term protocol when used as a supportive therapy for chronic inflammatory disorders.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rheutrop retard

The research base for Acemetacin has been explored through various study types, including trials and observational studies. This overview describes how Acemetacin was studied for research exploring outcomes related to physical discomfort and inflammatory states and highlights what aspects of the evidence are known, and what remains uncertain. The findings described here reflect group patterns observed in the studies and should not be used to predict individual outcomes.


Evidence for Use in Chronic Joint Conditions (Rheumatoid Arthritis and Osteoarthritis)

Research has explored the use of Acemetacin in adult populations experiencing conditions like Rheumatoid Arthritis (RA) and Osteoarthritis (OA). The types of research include historical trials and open multi-centre trials. Researchers primarily tracked patient-reported outcomes describing perceived discomfort and functional metrics. The available evidence describes symptom patterns observed over short- to intermediate-term observation periods. The evidence for these chronic indications is broadly classified as Moderate. However, many of the older trials used small sample sizes, and follow-up durations were limited for measuring long-term effects.

Evidence for Use in Ankylosing Spondylitis

Acemetacin was evaluated in studies involving adults with active Ankylosing Spondylitis (AS). This research includes large-scale prospective cohort studies and open multi-centre trials. Studies monitored changes in outcomes such as total and night back pain and formal scales that assess daily functioning or activity level. Data show patterns related to symptom scores in the observed groups, which sometimes included comparisons to other similar agents. A portion of the data comes from observational settings, which can have limitations related to non-randomized study designs.


What is Still Uncertain About the Research Base

The overall evidence quality varies across studies. Key areas of uncertainty include long-term effects which are not fully established by controlled trials, as follow-up durations were limited in many studies focusing on efficacy. Sample sizes were modest in some older trials, and subgroup findings are uncertain. Data for certain groups remain insufficient, particularly for pediatric populations or pregnant populations.

Key Studies & References Acemetacin: Uses, Interactions, Mechanism of Action | DrugBank Online

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rheutrop retard (FAQ)


Q: What is the difference between Rheutrop retard and regular Acemetacin capsules?

The term 'retard' refers to the modified-release formulation of the capsule. This design ensures that the active substance, Acemetacin, is released and absorbed slowly and consistently over an extended duration. This sustained action is designed to maintain steady therapeutic levels, which is generally different from immediate-release capsules.


Q: Is there a risk of heart-related issues, like high blood pressure, while taking Rheutrop retard?

Official regulatory documents warn of a class risk of serious arterial thrombotic events, such as heart attack or stroke, which may increase with the duration of use. Additionally, as with other NSAIDs, the medicine may cause fluid retention that can affect blood pressure control.


Q: Can Rheutrop retard cause fluid retention or swelling in the feet or ankles?

Yes, fluid retention and swelling, known as peripheral edema, are recognized adverse effects for the NSAID class of medicines. This is often linked to the potential effects this class of drugs can have on kidney function. Official product information emphasizes that caution is advised for patients who may be at risk.


Q: Is it normal to feel dizzy or drowsy after taking this medication?

Dizziness is specifically listed as a common side effect in official product information. While drowsiness is a possible central nervous system (CNS) effect that may occur, its frequency is variable. Official product information indicates that if these effects occur, patients should use caution when performing activities like driving.


Q: Can Rheutrop retard cause a skin rash or increased sun sensitivity?

A skin rash, which may indicate a hypersensitivity reaction, is listed as an uncommon adverse reaction in official product information. As with other NSAIDs, there may also be a general warning about increased sensitivity to sunlight, known as photosensitivity.


Q: Are there any specific foods or drinks that should be avoided while on this medication?

While there are no specific food groups typically restricted, it is officially advised to take the capsules with food, milk, or an antacid to help reduce the risk of stomach irritation. Regulatory sources caution against or advise limiting the concurrent use of alcohol due to the increased risk of gastrointestinal bleeding.


Q: What is the role of Rheutrop retard in treating conditions like gout?

Official therapeutic indications for this medicine often include the short-term treatment of acute attacks of gout. This is a common role for many Non-steroidal Anti-inflammatory Drugs due to their effective anti-inflammatory action.


Q: Is it true that Rheutrop retard can interfere with the protective effects of aspirin?

Regulatory documents warn that this medicine, like many other NSAIDs, may interfere with the anti-platelet effect of low-dose aspirin when it is used for cardiovascular protection. Official documents advise that patients taking low-dose aspirin for protection should have this potential interaction monitored by a healthcare professional.


Q: Is Rheutrop retard considered a strong painkiller?

Rheutrop retard is formally classified as a Non-steroidal Anti-inflammatory Drug (NSAID) and is a non-opioid medicine. Its primary purpose is to manage symptoms of pain and inflammation, classifying it as an analgesic and anti-inflammatory agent.


Q: What signs of a serious side effect should prompt immediate attention?

Official patient information indicates that serious symptoms, such as passing black, tarry stools or having difficulty breathing, require immediate medical attention. These signs may indicate gastrointestinal bleeding or a severe allergic reaction, respectively.


Q: Are there any known interactions between Rheutrop retard and alcohol?

Yes, regulatory documents caution that alcohol use should be limited or avoided. Using alcohol concurrently with this medicine may significantly increase the risk of serious side effects, most notably gastrointestinal bleeding.


Q: Can I take simple pain relievers like Paracetamol (Acetaminophen) along with Rheutrop retard?

Paracetamol (Acetaminophen) is not typically listed as a formal drug interaction in regulatory documents since it is not an NSAID. Regulatory guidance emphasizes the importance of monitoring the total dose of all analgesics taken to help prevent potential toxicity, and to avoid concurrent use with any other NSAID.


Q: How long does it typically take for Rheutrop retard to start relieving symptoms?

Due to the specialized modified-release formulation, the active substance is absorbed into the bloodstream slower than immediate-release forms. This means that achieving a therapeutic concentration for symptom relief may take longer after the initial dose.


Q: What should I do if I forget to take a dose of Rheutrop retard?

Regulatory instructions found in patient leaflets generally advise to skip the missed dose entirely. Patients are instructed to take the next dose at the regularly scheduled time and not to double the dose to make up for a forgotten capsule.


Q: Does Rheutrop retard contain any common allergens like lactose or gluten?

Official regulatory documentation, such as the Summary of Product Characteristics (SmPC), lists all excipients contained within the capsule. This includes the presence of known substances such as lactose. Patients with known intolerances are advised to review this component with their healthcare provider.


Q: Does Rheutrop retard contain any opioid ingredients?

No, Rheutrop retard is classified as a Non-steroidal Anti-inflammatory Drug (NSAID) based on its mechanism of action. It is a non-opioid medicine and does not contain any narcotic or opioid ingredients.


Q: Is there a generic version of Acemetacin slow-release available?

Yes, the active substance Acemetacin is available under various generic and brand names globally. However, the specific availability of an Acemetacin slow-release generic depends on the local country's drug registry and market authorization.


Q: Can Rheutrop retard affect my vision or cause ringing in the ears?

Uncommon or rare side effects associated with this medicine and the NSAID class include visual disturbances, such as blurred vision, and ringing in the ears, known as tinnitus. These effects are documented in regulatory adverse event sections and should be discussed with a healthcare professional if they occur.


Q: Does Rheutrop retard affect my ability to operate machinery or drive a car?

Regulatory documents include specific cautions regarding driving and operating machinery. This is because common side effects like dizziness, headache, and drowsiness can occur and potentially impair a patient's ability to safely perform these activities.


Q: Does Rheutrop retard help treat the underlying cause of arthritis?

No, Rheutrop retard is used for the symptomatic relief of pain and inflammation associated with conditions like arthritis. It works by modulating inflammatory pathways but is not classified as a disease-modifying antirheumatic drug (DMARD) and does not treat the underlying cause of the disease.

Advertisements

How should Rheutrop retard be stored and disposed of?

How to Store and Dispose of Rheutrop retard

The storage and disposal of Rheutrop retard (Acemetacin modified-release hard capsules) must adhere strictly to the conditions specified in official regulatory product information.

Storage Component Official Requirement
Temperature Store below 25 C in a cool and dry place.
Protection Keep the container tightly closed to protect the contents from light and moisture.
Child Safety Keep out of the sight and reach of children.
Stability Do not use the medicine after the expiry date (EXP) stated on the packaging.

Disposal must also follow specific guidelines. Unused or expired capsules must not be thrown away via wastewater or general household waste. Instead, patients must ask a pharmacist for instructions on proper disposal through established pharmaceutical waste or take-back schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rheutrop retard found in:

A-Z Index: